Clinical Scorecard: The Link Between Respiratory Viral Infections and Future Heart Failure: Considerations for Preventive Strategies
At a Glance
Category
Detail
Condition
Heart failure (HF) following respiratory viral infections (RVIs)
Key Mechanisms
Myocardial inflammation, endothelial dysfunction, systemic prothrombotic states, and acute myocardial injury induced by RVIs
Target Population
Patients aged 65 and older, individuals hospitalized with RVIs, and those with pre-existing HF
Care Setting
Hospital and outpatient cardiovascular and infectious disease care settings
Key Highlights
Hospitalization for RVIs is linked to a 45% increased risk of new-onset HF and a 28% increased risk of HF readmission within 180 days.
Respiratory syncytial virus (RSV) poses the highest risk for new-onset HF compared to influenza and COVID-19.
Vaccination against influenza, COVID-19, pneumococcal disease, and RSV significantly reduces the risk of HF events post-infection.
Guideline-Based Recommendations
Diagnosis
Perform routine cardiovascular risk assessments in patients aged 65 years and older following RVI hospitalization.
Management
Implement robust vaccination policies including influenza, COVID-19, pneumococcal, and RSV vaccines for at-risk populations.
Integrate vaccination with chronic disease management pathways, especially for patients with established HF.
Monitoring & Follow-up
Monitor patients hospitalized for RVIs for signs of new-onset HF or HF exacerbations for at least 6 months post-discharge.
Risks
Recognize that RSV infection carries a particularly high risk for subsequent HF events, independent of pre-existing cardiovascular conditions.
Acknowledge low vaccine uptake among HF patients as a missed preventive opportunity.
Patient & Prescribing Data
Patients hospitalized with influenza or COVID-19, and adults aged 60 years or older for RSV vaccination
Vaccination within the previous year or recent booster doses are associated with no significant increase in HF risk or readmission; influenza vaccination reduces all-cause mortality and rehospitalization in acute HF patients; RSV vaccination reduces cardiorespiratory and HF-specific hospitalizations.
Clinical Best Practices
Prioritize vaccination as a first-line cardiovascular preventive strategy in older adults and those with or at risk for HF.
Encourage multidisciplinary approaches combining vaccination with chronic disease management to improve vaccine uptake.
Educate patients and healthcare providers on the cardiovascular benefits of vaccination beyond infection prevention.
Maintain vigilant cardiovascular monitoring post-RVI hospitalization to detect and manage HF early.
